Elsevier

Journal of Critical Care

Volume 26, Issue 3, June 2011, Pages 329.e7-329.e14
Journal of Critical Care

Survival and quality of life after tracheostomy for acute respiratory failure in patients with amyotrophic lateral sclerosis

https://doi.org/10.1016/j.jcrc.2010.06.003Get rights and content

Abstract

Background

Acute respiratory failure (ARF) is a common event in the advanced stage of amyotrophic lateral sclerosis (ALS) and may be rarely a presenting symptom. Frequently, such patients require intubation and mechanical ventilation (MV) and, in a large proportion, receive tracheostomy, as a consequence of weaning failure. In our study, we investigated postdischarge survival and quality of life (QoL) after tracheostomy for ARF in patients with ALS.

Methods

Design: This study is a retrospective chart review combined with prospective evaluation of QoL and degree of depression. Setting: The study was conducted in an adult, respiratory intensive care unit in a university hospital. Patients: Amyotrophic lateral sclerosis patients with tracheostomy for ARF between January 1, 1995 and April 30, 2008 were investigated. Intervention and measurements: (a) A retrospective chart review was used and (b) prospective administration of the 11-item short-form Life Satisfaction Index (LSI-11) and Beck Depression Inventory (BDI) questionnaires to survivors, at least 1 month after discharge from hospital, was performed.

Results

Sixty patients were studied retrospectively. None of the patients died in the hospital after tracheostomy. Forty-two patients (70%) were discharged completely MV dependent, and 17 patients (28.3%) were partially MV dependent. One patient (1.6%) was liberated from MV.

The median survival after tracheostomy was 21 months (range, 0-155 months). The survival rate was 65% by 1 year and 45% by 2 years after tracheostomy. Survival was significantly shorter in patients older than 60 years at tracheostomy, with a hazard ratio of dying of 2.1 (95% confidence interval, 1.1-3.9). All 13 survivors completed the LSI-11 and BDI. The mean (SD) cumulative score on the LSI-11 was 9.3 (3.6; range, 0-22; higher values indicating better QoL), similar to that obtained from a control group consisting of individuals with ALS who had not received tracheostomy (9.3 ± 4.3) and to that reported for persons in the general population. Only 15% of the tracheostomized patients (2/13) were severely depressed, according to BDI; 11 of 13 patients reported a positive view of tracheostomy and said that they would want to undergo this procedure if they could make the decision again.

Conclusions

Patients with ALS have a high chance of long-term survival after tracheostomy for ARF. Although administered at the time of a respiratory crisis without being discussed in advance, tracheostomy shows good acceptance and results in acceptable QoL.

Introduction

Amyotrophic lateral sclerosis (ALS; also called motor neuron disease) is a devastating disease that involves both upper and lower motor neurons. It is the most common form of motor neuron disease, affecting approximately 1.2 to 1.8/100 000 individuals. Clinically, ALS is characterized by progressive muscular weakness leading to loss of the ability to move and speak and, in almost all patients, causes death between 3 and 5 years from diagnosis. Intellect and awareness remain essentially unchanged [1].

The onset of acute respiratory failure (ARF) due to diaphragm weakness, ineffective cough with airway mucous encumbrance, and inability to handle oropharyngeal secretions is a common event in the advanced stage of ALS and a major cause of death, unless mechanical ventilation (MV) is used [2], [3], [4], [5], [6]. Although noninvasive ventilation (NIV) combined with assisted coughing techniques can be a safer and more effective alternative to endotracheal intubation (ETI) in the treatment of neuromuscular ARF [7], [8], [9], individuals with ALS in most cases have to be excluded from NIV, due to the severe bulbar involvement with inability to adequately protect the airways, and require to be administered ETI. Unfortunately, most ALS patients who undergo invasive MV via ETI fails to wean adequately and may require tracheostomy and long-term MV (LTMV) [4], [6], [10]. The literature evaluating survival of ALS patients receiving LTMV via tracheostomy is disappointingly scarce and contains conflicting reports, with considerable variation among studies in the time between institution of this treatment and death [6], [10], [11], [12]. In addition, previous data suggest that life satisfaction may be poor for individuals with ALS who are administered tracheostomy at the time of a respiratory crisis without discussing this option in advance [12].

In such a situation, although beliefs and practice regarding end-of-life care may vary in different societies, many physicians in the intensive care unit (ICU) may be hesitant to administer invasive MV in the terminal phase of ALS, particularly if the patient has not requested in advance full support in the event of ARF [13], considering that this aggressive ventilatory approach may lead to an uncertain and sometimes unwanted prolongation of life and that the patient's dependence on ventilatory support may determine a dramatic physical and economic burden on family and caregivers after discharge from hospital [14], [15].

This paucity of information prompted us to review our 13-year experience of tracheostomy following ARF in ALS to determine postdischarge survival and identify those patient characteristics predicting long-term outcome. In addition, to gain a better understanding about the impact of tracheostomy on patients' quality of life (QoL) and degree of depression, we prospectively administered the 11-item short-form Life Satisfaction Index (LSI-11) [16] and Beck Depression Inventory (BDI) [17] questionnaires to survivors.

We hypothesized that our findings on the life expectancy and satisfaction after unplanned tracheostomy might help physicians in the ICU to face the challenging ethical dilemma associated with the management of patients with ALS who acutely require MV.

Section snippets

Methods

This study was approved by the institutional review board. Oral consent was obtained from all participants and their families for the interview portion of the study.

Survival

Sixty-one patients with ALS were admitted to our Unit as a result of ARF and were administered ETI and MV as an emergency procedure. None of the patients had expressed any advanced directives pertaining to the desire to undergo tracheotomy. One patient declined tracheostomy and died 35 days after intubation for severe pneumonia and septic shock. Sixty patients who had consented to tracheostomy met the study criteria and participated in the study. Clinical, demographic, and pulmonary function

Discussion

In the present study, postdischarge survival was retrospectively analyzed in a population of 60 patients with ALS who were administered tracheostomy after an episode of ARF, making it one of the largest studies on tracheostomy in ALS; in addition, QoL was prospectively evaluated in survivors. We demonstrated that patients have a high chance of long-term survival (median survival, 21 months; ranging from 0 to 155 months) and that age at tracheostomy is an independent prognostic factor for

References (40)

  • PhukanJ. et al.

    Cognitive impairment in amyotrophic lateral sclerosis

    Lancet Neurol

    (2007)
  • TulskyD.S. et al.

    Measurement of quality of life in rehabilitation medicine: emerging issues

    Arch Phys Med Rehabil

    (2003)
  • StrongM. et al.

    Amyotrophic Lateral Sclerosis: a review of current concepts

    Amyotroph Lateral Scler Other Motor Neuron Disord

    (2003)
  • Al-ShaikhB. et al.

    Motor neurone disease presenting as respiratory failure

    BMJ

    (1986)
  • ChenR. et al.

    Motor neuron disease presenting as acute respiratory failure: a clinical and pathological study

    J Neurol Neurosurg Psychiatry

    (1996)
  • HadjikoutisS. et al.

    Respiratory complications related to bulbar dysfunction in motor neuron disease

    Acta Neurol Scand

    (2001)
  • BradleyM.D. et al.

    Outcome of ventilatory support for acute respiratory failure in motor neurone disease

    J Neurol Neurosurg Psychiatry

    (2002)
  • VianelloA. et al.

    Non-invasive ventilatory approach to treatment of acute respiratory failure in neuromuscular disorders. A comparison with endotracheal intubation

    Int Care Med

    (2000)
  • VianelloA. et al.

    Mechanical insufflation-exsufflation improves outcomes for neuromuscular disease patients with respiratory tract infections

    Am J Phys Med Rehabil

    (2005)
  • ServeraE. et al.

    Alternative to endotracheal intubation for patients with neuromuscular diseases

    Am J Phys Med Rehabil

    (2005)
  • Cited by (90)

    • Amyotrophic lateral sclerosis: An emblematic neurodegenerative disease

      2023, Bulletin de l'Academie Nationale de Medecine
    • Palliative care principles in ALS

      2023, Handbook of Clinical Neurology
    View all citing articles on Scopus

    Statement of interests: We all Authors declare that we have no financial and personal relationships with people or organizations that could have inappropriately influenced (bias) our work. No study sponsor has been involved in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. We have no conflicts of interest to declare.

    View full text